Patient preferences for an oral anticoagulant after major orthopedic surgery: Results of a German survey

Patient

Volumn 2, Issue 1, 2009, Pages 39-49

  Wilke, Thomas ^a  

^a Hochschule Wismar   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN ETEXILATE; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; DRUG HYPERSENSITIVITY; DRUG PREFERENCE; FEMALE; GERMANY; HEALTH CARE COST; HEMATOMA; HIP ARTHROPLASTY; HOSPITAL; HUMAN; INTERVIEW; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; PATIENT ATTITUDE; PRIORITY JOURNAL; THROMBOSIS;

EID: 77953436481     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.2165/01312067-200902010-00005     Document Type: Article

References (20)

1. Colwell Jr CW. Thromboprophylaxis in orthopaedic surgery. Am J Orthop 2006; Suppl:1-9: quiz 10-1
2. Böttner F, Sulco TP, Sharrock NE, et al. Thromboprophylaxis after hip surgeries [in German]. Orthopäde 2001; 30: 890-6
3. Van Aken H, Bode C, Darius H, et al. Anticoagulation: the present and future. Clin Appl Thromb Hemost 2001; 7: 195-204
4. Hawkins D. Pharmacoeconomics of thrombosis management. Pharmacotherapy 2004; 24: 95-9S
5. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2005; 126 (3 Suppl.): 338-400S
6. AWMF. Inpatient and outpatient thromboprophylaxis in surgical and pre-surgical cases [in German; online]. Available from URL: http://www.uni- duesseldorf.De/awmf/ll/003-001. htm [Accessed 2009 Jan 5]
7. Lipp H-P, Goldinger A, Haussmann W, et al. Anti-thrombotics for therapy and prophylaxis of venous thromboembolism [in German]. Krankenhauspharmazie 2004; 25: 195-210, 303-15
8. Eriksson BI, Dahl OE, Bueller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-11
9. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial [published erratum appears in Lancet 2007; 370: 2004]. Lancet 2007; 370: 949-56
10. Wilke T, Neumann K, Klapper U, et al. Oral anti-coagulation after hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals [in German]. Orthopäde 2008; 37: 448-56
11. Statistical development of population and households [in German]. Publication VI A 1. Wiesbaden: Statistisches Bundesamt, 2007
12. Gustafsson A, Herrmann A, Huber F, editors. Conjoint measurement: methods and applications. Berlin: Springer, 2007
13. Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics 2008; 26 (8): 661-77
14. Hait JF, Black WC, Babin BJ, et al. Multivariate data analysis. 6th edition. Upper Saddle River (NJ): Pearson-Prentice Hall, 2005
15. Moore WL, Gray-Lee J, Louviere JJ. A cross-validity comparison of conjoint analysis and choice models at different levels of aggregation. Marketing Letters 1998; 9: 195-207
16. Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. New York: Marcel Dekker, 2004
17. Schoeffski O, Schulenburg J-M, Graf VD, editors. Evaluations in health economics [in German]. 3rd ed. Berlin: Springer, 2007
18. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med 1992; 34: 507-13
19. Spahn G. Compliance with self administration of heparin injections in outpatients. Eur J Trauma 2002; 2: 104-9
20. Tribout B, Colin-Mercier F. New versus established drugs in venous thromboprophylaxis: efficacy and safety considerations related to timing of administration. Am J Cardiovasc Drugs 2007; 7: 1-15